Singapore-based medtech startup Us2.ai, which uses machine learning to automate the fight against heart disease, has raised US$15 million in a Series A round led by IHH Healthcare and Australian healthcare-focused fund Heal Partners.
Lifesciences-focused Pappas Capital and existing investors joined the round, including Sequoia India, EDBI, and Partech Ventures.
The firm will use the funds to drive its growth targets for clinical implementation in the US, Europe and Asia. In addition, US2.ai plans to expand its commercial activities with leading pharmaceutical companies, research labs, and imaging providers worldwide.
“Our focus has been to create a comprehensive solution beyond the existing industry standard of partial automation requiring manual intervention and providing limited measurements,” said James Hare, CEO and co-founder of Us2.ai. “Our software automatically processes full echocardiographic studies of 2D and Doppler images from any vendor in less than two minutes. It thus delivers complete echo reports, with fully explainable measurements, editable annotations and conclusions for every heart chamber.”
Also Read: New technology that’s challenging the status quo in medicine
Us2.ai’s software tools improve clinical decision making and cardiovascular research for clinical trials using echocardiography, the safest cardiac imaging modality. It connects institutions and imaging labs worldwide on a platform of ready-to-use automation tools for view classification, segmentation and federated learning across diverse, anonymous patient and disease cohorts.
Its product Us2.v1 has automated measurements that include 2D (cardiac volumes, all four chambers of the heart), M-mode (e.g. tricuspid annular plane systolic excursion), spectral Doppler (blood flow across all valves, both PW and CW measurements) and tissue Doppler. They have covered most standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography, European Association of Cardiovascular Imaging, and British Society of Echocardiography.
Fully automated Us2.v1 measurements were utterly interchangeable with expert human measurements and were completely reproducible for a given patient study.
Us2.ai has completed multiple projects with global pharmaceutical partners and a groundbreaking approval study at the Brigham & Women’s Hospital.
—
Ready to meet new startups to invest in? We have more than hundreds of startups ready to connect with potential investors on our platform. Create or claim your Investor profile today and turn on e27 Connect to receive requests and fundraising information from them.
The post US2.ai secures US$15M Series A to automate fight against heart disease appeared first on e27.